Business Description
Duality Biotherapeutics Inc
SIC : 2836
ISIN : KYG2929M1087
Total Employee Number:
231Compare
Compare
Traded in other countries / regions
09606.Hong Kong4ZB.Germany IPO Date
2025-05-06Description
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.04 | |||||
Beneish M-Score | -6.04 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1043.5 | |||||
3-Year EBITDA Growth Rate | -103.8 | |||||
3-Year EPS without NRI Growth Rate | -103.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.74 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.54 | |||||
9-Day RSI | 28.51 | |||||
14-Day RSI | 32.35 | |||||
3-1 Month Momentum % | 20.59 | |||||
6-1 Month Momentum % | -15.75 | |||||
12-1 Month Momentum % | -55.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.99 | |||||
Quick Ratio | 1.99 | |||||
Cash Ratio | 1.74 | |||||
Days Sales Outstanding | 102.47 | |||||
Days Payable | 276.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -1.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -28.7 | |||||
Operating Margin % | -179.73 | |||||
Net Margin % | -173.82 | |||||
EBITDA Margin % | -172.65 | |||||
FCF Margin % | -102.73 | |||||
OCF Margin % | -98.63 | |||||
ROE % | -65.1 | |||||
ROA % | -38 | |||||
ROIC % | -386.18 | |||||
3-Year ROIIC % | 9.4 | |||||
ROC (Joel Greenblatt) % | -5621.96 | |||||
ROCE % | -55.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 16.98 | |||||
PB Ratio | 9.69 | |||||
Price-to-Tangible-Book | 9.7 | |||||
EV-to-EBIT | -8.13 | |||||
EV-to-Forward-EBIT | -9.5 | |||||
EV-to-EBITDA | -8.18 | |||||
EV-to-Forward-EBITDA | -74.75 | |||||
EV-to-Revenue | 14.11 | |||||
EV-to-Forward-Revenue | 9.78 | |||||
EV-to-FCF | -12.95 | |||||
| Price-to-Net-Current-Asset-Value | 9.95 | |||||
| Price-to-Net-Cash | 14.38 | |||||
Earnings Yield (Greenblatt) % | -12.3 | |||||
FCF Yield % | -5.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Duality Biotherapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 102.353 | ||
| EPS (TTM) (€) | -1.971 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 53.4 | ||
| 14-Day RSI | 32.35 | ||
| 14-Day ATR (€) | 0.619307 | ||
| 20-Day SMA (€) | 20.385 | ||
| 12-1 Month Momentum % | -55.27 | ||
| 52-Week Range (€) | 18.3 - 56 | ||
| Shares Outstanding (Mil) | 90.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Duality Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Duality Biotherapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Duality Biotherapeutics Inc Frequently Asked Questions
What is Duality Biotherapeutics Inc(FRA:4ZB)'s stock price today?
The current price of FRA:4ZB is €19.70. The 52 week high of FRA:4ZB is €56.00 and 52 week low is €18.30.
When is next earnings date of Duality Biotherapeutics Inc(FRA:4ZB)?
The next earnings date of Duality Biotherapeutics Inc(FRA:4ZB) is .
Does Duality Biotherapeutics Inc(FRA:4ZB) pay dividends? If so, how much?
Duality Biotherapeutics Inc(FRA:4ZB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers